MetaCap

ADC Therapeutics SA (ADCT) vs Korro Bio (KRRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Korro Bio (KRRO) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 93.9% versus a loss of 68.2%. Over five years, ADCT leads with a -94.2% price change compared with -95.7% for KRRO. ADC Therapeutics SA is the larger company by market cap ($180.0 million vs $167.2 million), about 1.1 times the size, while Korro Bio is growing revenue faster (+181.5% vs +14.9%).

ADC Therapeutics SA converts more of its revenue into profit, with a net margin of -175.3% versus -1834.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADCT-68.16%KRRO+93.95%
+177%+44%-88%
Nov 21, 20251 yearNov 20, 2026
ADCT-94.40%KRRO-95.95%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADCT versus KRRO key metrics
MetricADCTKRRO
Share price$1.28$12.18
Market cap$180.05M$167.18M
1-day change-1.54%-0.08%
YTD return-63.74%+52.06%
1-year return-68.16%+93.95%
5-year return-94.23%-95.67%
EPS (TTM)$-0.46$-8.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$81.36M$6.39M
Revenue growth (YoY)+14.85%+181.46%
Net income (latest FY)$-142.62M$-117.26M
Gross margin92.87%—
Operating margin-149.34%-1906.37%
Net margin-175.31%-1834.48%
52-week high$4.98$17.35
52-week low$0.78$5.20
Distance from 52-week high-74.30%-29.81%
Analyst consensusbuystrong_buy
Avg. price target upside+160.16%+76.52%
Average volume1.55M186.03K
Shares outstanding140.66M13.73M
Employees18858
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRRO has outperformed ADCT by 162.1 percentage points over the past year.
  • ADC Therapeutics SA is more profitable, keeping -175.3 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.
  • Korro Bio grew revenue faster in its latest fiscal year (+181.46% vs +14.85%).

About ADC Therapeutics SA

ADCT stock →

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.

Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees

About Korro Bio

KRRO stock →

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

ADCT vs KRRO FAQ

Which is bigger, ADC Therapeutics SA or Korro Bio?

ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $180.05M compared with $167.18M for Korro Bio (KRRO).

Which stock has performed better over the past year, ADCT or KRRO?

KRRO returned +93.95% over the past 12 months, compared with -68.16% for ADCT (price return, excluding dividends). Past performance does not predict future results.

Are ADC Therapeutics SA and Korro Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons